Pricing Wars and Policy Shifts: The Economics of GLP-1 Access
Despite the overwhelming clinical success of incretin therapies, the GLP-1 Drug Market faces intense scrutiny regarding drug pricing, affordability, and equitable patient access. Historically, the list price for a month's supply of branded injectable GLP-1s for weight loss in the United States hovered between $1,000 and $1,350. This exorbitant cost, combined with widespread reluctance among...
0 Commentarii 0 Distribuiri 412 Views 0 previzualizare
SocioMint https://sociomint.com